Aligos Therapeutics, Inc. (ALGS): R&D Expense
$69.45M
Year ended 2025-12-31
$88.38M
Trailing 12 months to 2026-06-30
-6.5%
3-year compound annual growth
-2.8%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $69.45M | -1.2% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $70.27M | -3.8% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $73.04M | -14.1% | 2025-03-10, From 2023-01-01 |
| 2022-12-31 | $85.08M | -18.3% | 2024-03-12, From 2022-01-01 |
| 2021-12-31 | $104.15M | +30.4% | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $79.89M | +81.4% | 2022-03-10, From 2020-01-01 |
| 2019-12-31 | $44.04M | n/a | 2021-03-23, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $69.45M | -1.2% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $69.30M | -21.8% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $2.15M | +5.4% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $27.18M | -34.9% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $29.36M | +39.0% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $284.81M | -8.2% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $2.37M | -57.2% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $113.03M | -44.5% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $116.64M | +42.1% |
Compare ALGS, HUMA, DYAI, OTLK side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗